Dime Community Bancshares, Inc. (DCOM)
NASDAQ: DCOM · Real-Time Price · USD
29.71
+0.70 (2.41%)
At close: Aug 13, 2025, 4:00 PM
29.70
-0.01 (-0.03%)
After-hours: Aug 13, 2025, 4:00 PM EDT
Oncternal Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Interest Income on Loans | 587.98 | 590.49 | 554.49 | 406.6 | 359.02 | 216.57 | Upgrade |
Interest Income on Investments | 71.16 | 59.66 | 54.87 | 32.62 | 25.61 | 17.44 | Upgrade |
Total Interest Income | 659.14 | 650.15 | 609.36 | 439.23 | 384.63 | 234.01 | Upgrade |
Interest Paid on Deposits | 257.05 | 284.75 | 219.05 | 38.43 | 16.53 | 33.04 | Upgrade |
Interest Paid on Borrowings | 38.75 | 47.35 | 73.74 | 20.93 | 10.49 | 23.27 | Upgrade |
Total Interest Expense | 295.81 | 332.1 | 292.79 | 59.36 | 27.02 | 56.3 | Upgrade |
Net Interest Income | 363.33 | 318.05 | 316.57 | 379.86 | 357.61 | 177.7 | Upgrade |
Net Interest Income Growth (YoY) | 22.07% | 0.47% | -16.66% | 6.22% | 101.24% | 20.54% | Upgrade |
Gain (Loss) on Sale of Assets | 0.56 | 7.22 | -0.02 | 1.4 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -42.51 | -44.01 | -2.21 | - | 1.84 | 4.95 | Upgrade |
Other Non-Interest Income | 36.24 | 32.21 | 36.73 | 34.51 | 31.95 | 19.91 | Upgrade |
Total Non-Interest Income | -5 | -3.96 | 36.21 | 38.16 | 58.57 | 27.87 | Upgrade |
Non-Interest Income Growth (YoY) | - | - | -5.11% | -34.86% | 110.17% | 129.04% | Upgrade |
Revenues Before Loan Losses | 358.33 | 314.1 | 352.78 | 418.02 | 416.18 | 205.57 | Upgrade |
Provision for Loan Losses | 44.17 | 36.11 | 2.77 | 5.37 | 6.21 | 26.17 | Upgrade |
314.17 | 277.99 | 350.01 | 412.65 | 409.97 | 179.41 | Upgrade | |
Revenue Growth (YoY) | -1.94% | -20.58% | -15.18% | 0.65% | 128.51% | 26.12% | Upgrade |
Salaries and Employee Benefits | 136.42 | 129.42 | 112.8 | 115.83 | 102.92 | 53.53 | Upgrade |
Occupancy Expenses | 16.38 | 16.08 | 16.25 | 18.79 | 16.36 | 9.66 | Upgrade |
Federal Deposit Insurance | 7.96 | 8.71 | 8.85 | 3.9 | 4.08 | 2.26 | Upgrade |
Amortization of Goodwill & Intangibles | 1.06 | 1.16 | 1.43 | 1.88 | 2.62 | - | Upgrade |
Selling, General & Administrative | 55.97 | 53.42 | 46.85 | 44.85 | 50.33 | 26.93 | Upgrade |
Other Non-Interest Expense | 16.45 | 14.78 | 17.86 | 12.54 | 13.94 | 6.75 | Upgrade |
Total Non-Interest Expense | 234.24 | 223.58 | 204.04 | 197.79 | 190.25 | 99.12 | Upgrade |
EBT Excluding Unusual Items | 79.93 | 54.4 | 145.97 | 214.85 | 219.72 | 80.29 | Upgrade |
Other Unusual Items | -8.45 | -1.67 | - | -0.74 | -19.8 | -6.05 | Upgrade |
Pretax Income | 70.01 | 51.44 | 136.88 | 211.92 | 148.17 | 54.98 | Upgrade |
Income Tax Expense | 25.94 | 22.36 | 40.79 | 59.36 | 44.17 | 12.67 | Upgrade |
Net Income | 44.07 | 29.08 | 96.09 | 152.56 | 104 | 42.32 | Upgrade |
Preferred Dividends & Other Adjustments | 7.94 | 7.66 | 8.53 | 8.97 | 8.5 | 4.93 | Upgrade |
Net Income to Common | 36.13 | 21.42 | 87.57 | 143.58 | 95.5 | 37.39 | Upgrade |
Net Income Growth | -34.68% | -69.73% | -37.01% | 46.69% | 145.75% | 16.95% | Upgrade |
Basic Shares Outstanding | 41 | 39 | 38 | 39 | 39 | 22 | Upgrade |
Diluted Shares Outstanding | 41 | 39 | 38 | 39 | 39 | 22 | Upgrade |
Shares Change (YoY) | 7.92% | 1.95% | -0.91% | -0.94% | 80.62% | -7.11% | Upgrade |
EPS (Basic) | 0.88 | 0.55 | 2.29 | 3.73 | 2.45 | 1.74 | Upgrade |
EPS (Diluted) | 0.87 | 0.55 | 2.29 | 3.73 | 2.45 | 1.74 | Upgrade |
EPS Growth | -43.48% | -75.98% | -38.53% | 52.07% | 41.14% | 11.99% | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 0.990 | 0.960 | 0.960 | - | Upgrade |
Dividend Growth | - | 1.01% | 3.13% | - | - | - | Upgrade |
Effective Tax Rate | 37.06% | 43.46% | 29.80% | 28.01% | 29.81% | 23.04% | Upgrade |
Updated Jul 24, 2025. Source: S&P Global Market Intelligence. Banks template. Financial Sources.